Please provide your email address to receive an email when new articles are posted on . The approval follows positive results from the TATE trial. A new 10 mg dose will be available to accommodate ...

Asthma season is in full swing and AstraZeneca is raising awareness about its severe asthma treatment, Fasenra, as part of its ongoing Stepping Back Out campaign. The latest installment of the ...

Teaming with the Professional Pickleball Association (PPA) in a multiyear deal, AstraZeneca’s seven-year-old Fasenra asthma medication has launched its first-ever sports partnership. The brand began ...

Dr. Michael Wechsler, Professor of Medicine and Director of The Asthma Institute at National Jewish Health, and International Coordinating Investigator of the MANDARA trial said: “This approval is ...

AstraZeneca experienced some setbacks last year on its quest to expand its asthma drug Fasenra to treat other conditions like rhinosinusitis and eosinophilic esophagitis. However, the British pharma ...

No new safety signals were identified in the pediatric trial. The Food and Drug Administration (FDA) has expanded the approval of Fasenra (benralizumab) for add-on maintenance treatment of severe ...

AstraZeneca is stepping back into Fasenra promotion to show how its asthma treatment can help people with asthma step back out. The ad opens with a feed of social media posts on a tablet screen. In ...

AstraZeneca AZN announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab), for use in children. The regulatory body has now approved Fasenra as an add-on maintenance ...

Jessica Eckard has always had asthma problems. Her father died of tuberculosis when she was young, she had struggled with breathing during gym class and was even told by her swim instructor to "never ...

AstraZeneca is refreshing its Fasenra campaign. Almost six years into the launch, the Big Pharma has established consistent messaging across physicians and patients for the first time, tying the brand ...

The FINANCIAL — AstraZeneca and its global biologics research and development arm, MedImmune, on January 10 announced that the European Commission (EC) has approved Fasenra (benralizumab) as an add-on ...